Advertisements



We are Sorry, This Page doesn't Exist


Exelixis, Roche slide after colon cancer drug fails to meet primary study goal

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2018

Immune therapy doubles lung cancer survival rate

New drugs that trigger a patient’s immune system to kill malignant cells can greatly improve the survival rate of people with the most common type of lung cancer, a new study found. The study, published in the New England Journal of Medicine, found.....»»

Category: topSource: bizjournalsApr 17th, 2018

New Drug Combinations Improve Survival in Lung Cancer

Combining expensive cancer immunotherapies with each other or with older drugs prolonged survival in lung cancer patients, two studies show. But the costs are high......»»

Category: smallbizSource: wsjApr 17th, 2018

Brainstorm Health: Merck’s Lung Cancer Triumph, COPD and Women, Trump on Drug Prices

Brainstorm Health Daily: April 16, 2018 Hello and happy Monday, readers! This is Sy. New study results released Monday continue to cement drug giant Merck’s status as the force to be r.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck shares rise after beating rivals" lung cancer results

In a fierce rivalry to prove cancer drug combinations work better for advanced.....»»

Category: topSource: marketwatchApr 16th, 2018

This Lung Cancer Drug Could Let Patients Forgo Chemo—And It’s Sending Merck’s Stock Soaring

Merck gained.....»»

Category: europeSource: fortuneApr 9th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

Form D Friday: Fort Worth venture capital firm to invest in New York cancer drug maker

Bios Partners is preparing to make an investment in a New York cancer treatment developer Incysus......»»

Category: topSource: bizjournalsMay 18th, 2018

This Tiny Cancer Drug Upstart Just Got Even More Interesting

A clinical-stage cancer drug company could be on the cusp of a second big win......»»

Category: topSource: foxnewsMay 18th, 2018

Anti-fungal Drug Resistance As Serious As the Antibiotic Apocalypse, Warn Scientists

Anti-fungal resistance is a "serious and immediate threat" estimated to be killing more people that breast cancer and malaria......»»

Category: topSource: newsweekMay 18th, 2018

Loxo Oncology shares surge 21% on preview of cancer drug trial data

Loxo Oncology Inc. shares surged 20.8% in heavy Thursday mo.....»»

Category: topSource: marketwatchMay 17th, 2018

Loxo Oncology shares surge nearly 20% on preview of cancer drug trial data

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchMay 17th, 2018

Shorter drug treatment OK for many breast cancer patients

Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests......»»

Category: topSource: foxnewsMay 16th, 2018

B Riley Likes Tocagen On Prospects For Company"s Brain Cancer Drug

A little more than a year after its initial public offering, Tocagen Inc (NASDAQ: TOCA) has traded down 26 percent, but experts are decidedly bullish on the company’s prospects and potential valuation. Latest Ratings for TOCA DateFirmAction.....»»

Category: blogSource: benzingaMay 16th, 2018

Redner"s marijuana home-grow battle goes to Florida Supreme Court

Arguing that “emergency relief is clearly warranted and urgently needed,” attorneys for a Tampa businessman are asking the Florida Supreme Court to step into a legal battle and allow the lung cancer patient to grow medical marijuana for his own.....»»

Category: topSource: bizjournalsMay 16th, 2018

Startup aims to give castoff Vertex drug new life as Alzheimer’s treatment

In 2001, Vertex Pharmaceuticals announced that it was halting development of a rheumatoid arthritis drug. The treatment, which was designed to block a certain enzyme linked to inflammation, had showed promise in clinical trials, but animal studies .....»»

Category: topSource: bizjournalsMay 16th, 2018

A big drugmaker is backing away from a plan to triple the price of a lifesaving cancer drug after facing a public backlash

Thomson Reuters Drugmaker Pharmacyclics had tripled the cost of a lifesaving cancer blood treatment when it introduced a new version of the pill. The new price tag faced criticism from cance.....»»

Category: topSource: businessinsiderMay 16th, 2018

Kanpur, the world"s most polluted city, struggles to contain disease

Problems from air pollution are leading to multiple diseases such as lung cancer, bronchial asthma, chronic obstructive pulmonary disease and pneumonia.....»»

Category: topSource: business-standardMay 15th, 2018

Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)

A fast growing cancer drug Blockbuster vaccines Significant challenges All three of these apply to Pfizer NYSE PFE but they also all apply to Merck NYSE MRK Both pharmaceutical companies have successful 160 products with sizzling sales but both have.....»»

Category: futuresSource: nasdaqMay 13th, 2018